NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD
1.5
+0.03 (+2.04%)
The current stock price of CBUS is 1.5 USD. In the past month the price decreased by -45.45%. In the past year, price decreased by -85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.04 | 327.31B | ||
AMGN | AMGEN INC | 13.94 | 155.58B | ||
GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.33 | 26.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
NTRA | NATERA INC | N/A | 23.47B | ||
INSM | INSMED INC | N/A | 18.70B | ||
BIIB | BIOGEN INC | 8.03 | 18.62B |
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 157 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 158
Phone: 18584500008
The current stock price of CBUS is 1.5 USD. The price increased by 2.04% in the last trading session.
The exchange symbol of CIBUS INC is CBUS and it is listed on the Nasdaq exchange.
CBUS stock is listed on the Nasdaq exchange.
10 analysts have analysed CBUS and the average price target is 17.34 USD. This implies a price increase of 1056% is expected in the next year compared to the current price of 1.5. Check the CIBUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CIBUS INC (CBUS) has a market capitalization of 51.57M USD. This makes CBUS a Micro Cap stock.
CIBUS INC (CBUS) currently has 158 employees.
CIBUS INC (CBUS) has a resistance level at 2.28. Check the full technical report for a detailed analysis of CBUS support and resistance levels.
The Revenue of CIBUS INC (CBUS) is expected to grow by 34.19% in the next year. Check the estimates tab for more information on the CBUS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CBUS does not pay a dividend.
CIBUS INC (CBUS) will report earnings on 2025-08-06.
CIBUS INC (CBUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.69).
The outstanding short interest for CIBUS INC (CBUS) is 6.53% of its float. Check the ownership tab for more information on the CBUS short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CBUS. CBUS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -2.69. The EPS increased by 85.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -82.03% | ||
ROE | -391.1% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to CBUS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 10.29% and a revenue growth 34.19% for CBUS